Hypercholesterolemia Treatment through LDL Receptor regulation
The technology suggests the development of new signal transduction-based approach for the treatment of hypercholesterolemia. By developing a hepatic cell line in which the Raf-1 pathway can be induced specifically and strongly, researchers have now found that Raf-1/MEK-1/2 p42MAPK plays a central role in regulating LDL receptor expression, and the degree of p42/44MAPK activation determines the extent of LDL receptor induction. This study also highlighted that p42/44MAPK is critical in regulating LDL receptor expression. This information will help in understanding the pathologic states under which the receptor pathways are perturbed resulting in hypercholesterolemia. Furthermore, the technology also proposes inducers of p42/44MAPK that can act as excellent agents to treat hypercholesterolemia.
Sector: Pharmaceuticals
Country: India
Area of Application: Receptor regulation,low density lipoprotein
Keywords: Receptor regulation
Advantages: New signal transduction-based approaches for the treatment of hypercholesterolemia Determines LDP expression in an individual Useful in screening a candidate compound having stimulatory effect Helps in the regulation of cholesterol in the patient body
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent
Technical specifications:
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
City: Ahmedabad
Country: India
Zip/Pin Code: 380054